<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen S Gottlieb, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1516265544"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Heart failure (HF) is a clinical syndrome caused by impairment of ventricular filling or ejection of blood [<a href="#rid1">1</a>], which results in the inability of the heart to provide adequate perfusion to the tissues while maintaining normal cardiac filling pressures. HF is associated with a variety of interrelated structural, functional, and neurohumoral alterations with beneficial as well as maladaptive effects.</p><p>This topic will discuss the hemodynamic and remodeling aspects of the pathophysiology of HF, particularly HF with reduced ejection fraction (HFrEF; left ventricular ejection fraction [LVEF] ≤40 percent) and HF with mid-range ejection fraction (HFmrEF; LVEF 41 to 49 percent). The pathophysiology of neurohormonal alternations in HF, the diagnosis and management of HFrEF and HFmrEF, and the pathogenesis of HF with preserved ejection fraction (HFpEF, LVEF ≥50 percent) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3481.html" rel="external">"Pathophysiology of heart failure: Neurohumoral adaptations"</a> and  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a> and  <a class="medical medical_review" href="/z/d/html/117708.html" rel="external">"Treatment and prognosis of heart failure with mildly reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/3457.html" rel="external">"Pathophysiology of heart failure with preserved ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p class="headingAnchor" id="H433020782"><span class="h1">LVEF CATEGORIES AND LIMITATIONS</span><span class="headingEndMark"> — </span>As discussed below, the two major types of ventricular dysfunction that lead to HF are systolic dysfunction (impaired cardiac contractile function) and diastolic dysfunction (impaired cardiac filling), although these mechanisms are often concurrent (see <a class="local">'Pressure-volume relationships in HF'</a> below). For clinical purposes, HF due to LV dysfunction is categorized according to LVEF. Nearly one-half of patients with HF have HFrEF (LVEF ≤40 percent), and nearly one-half have HFpEF (LVEF ≥50 percent) [<a href="#rid2">2</a>]. The remaining 10 to 24 percent of patients with HF have HFmrEF (LVEF 41 to 49 percent) [<a href="#rid3">3-14</a>].</p><p>However, categorization of LV function and HF by LVEF is not based upon etiology or pathophysiology, but rather by clinical convention given the prognostic value of LVEF, inclusion of LVEF thresholds as criteria in clinical HF trials, and the widespread availability of methods to measure LVEF (particularly echocardiography). LVEF is not a robust measure of contractility [<a href="#rid15">15</a>], commonly changes over time, and is subject to substantial variability among and within modalities. (See <a class="local">'Contractility'</a> below and  <a class="medical medical_review" href="/z/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function", section on 'Left ventricular ejection fraction'</a>.)</p><p>Patients with the same LVEF may have differing underlying pathophysiology and prognosis. Despite these limitations, depressed LVEF is an adverse prognostic indicator in HF patients, with increasing morbidity and mortality as LVEF falls below 40 to 50 percent. (See  <a class="medical medical_review" href="/z/d/html/3477.html" rel="external">"Predictors of survival in heart failure with reduced ejection fraction", section on 'Left ventricular ejection fraction'</a> and  <a class="medical medical_review" href="/z/d/html/3501.html" rel="external">"Prognosis of heart failure", section on 'Factors affecting mortality rates'</a>.)</p><p class="headingAnchor" id="H1568377579"><span class="h1">NORMAL LV PRESSURE-VOLUME RELATIONSHIP</span><span class="headingEndMark"> — </span>As a pump, the ventricle generates pressure and displaces a volume of blood. The three major determinants of LV performance (reflected as stroke volume) are the preload (reflected by venous return and end-diastolic volume), myocardial contractility (the force generated at any given end-diastolic volume), and the afterload (aortic impedance and wall stress) [<a href="#rid16">16</a>]. The relationship between LV pressure generation and ejection can be expressed as a plot of LV pressure versus LV volume  (<a class="graphic graphic_figure graphicRef73169" href="/z/d/graphic/73169.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H3854204765"><span class="h2">Preload</span><span class="headingEndMark"> — </span>Preload is defined as the particular stretch or length of LV myocardial fibers at end-diastole, which is determined by the resting force, myocardial compliance, and the degree of filling from the left atrium. Landmark studies by Frank and Starling established the relationship between ventricular end-diastolic volume (which is a measure of preload) and ventricular performance (stroke volume). Increasing sarcomere length up to a point increases the degree of overlap between actin and myosin filaments for force-generating cross-bridges, thereby enabling increased tension development  (<a class="graphic graphic_figure graphicRef63547" href="/z/d/graphic/63547.html" rel="external">figure 2</a>) [<a href="#rid17">17</a>]. Thus, there is an augmentation of developed force as end-diastolic volume and fiber length increase up to a point. The LV normally functions on the ascending limb of this force-length relationship.</p><p class="headingAnchor" id="H3518866058"><span class="h2">Contractility</span><span class="headingEndMark"> — </span>Myocardial contractility is defined by the force generated at any given preload. Thus, the stroke volume at any given fiber length is a function of contractility, as variations in contractility create nonparallel shifts in the developed force-length relation. The tension in each myocardial cell is a function of the amount of calcium bound to a regulatory site on the troponin complex of the myofilaments. The amount of calcium available is in turn a function of intracellular calcium delivery.</p><p>Although LVEF is often assumed to be a measure of cardiac function, it is important to recognize the profound effect of structural changes. LV remodeling results in myocyte lengthening that increases chamber volume and results in an obligatory reduction in LVEF not necessarily caused by impaired contractile function. (See <a class="local">'Remodeling'</a> below.)</p><p class="headingAnchor" id="H2453585929"><span class="h2">Afterload</span><span class="headingEndMark"> — </span>A third element determining ventricular performance is the afterload, the impedance during ejection. The afterload on the shortening fibers is defined as the force per unit area acting in the direction in which these fibers are arranged in the ventricular wall. This constitutes the wall stress and can be estimated by applying Laplace's Law [<a href="#rid18">18</a>]. Changes in ventricular volume and wall thickness, as well as aortic pressure or aortic impedance, determine the afterload. As an example, elevations in systolic pressure reduce the ventricular stroke volume at any given diastolic volume. In the normal heart, stroke volume is only minimally altered by changes in afterload.</p><p>The relationship among preload, afterload, and contractility provides a type of feedback control of myocardial function. A primary increment in stroke volume, for example, leads to an increase in aortic impedance. As a result of this rise in afterload, subsequent contractions have an attenuated stroke volume. If, on the other hand, an increment in aortic impedance is the initial event, the accompanying reduction in stroke volume should lead to a greater end-ejection and end-diastolic chamber volume. The ensuing prolongation of fiber length should restore stroke volume to the baseline level.</p><p class="headingAnchor" id="H2453283001"><span class="h1">PRESSURE-VOLUME RELATIONSHIPS IN HF</span><span class="headingEndMark"> — </span>The two major types of ventricular dysfunction that lead to HF are systolic dysfunction (impaired cardiac contractile function) and diastolic dysfunction (impaired cardiac filling), although these mechanisms are interrelated and often concurrent. Systolic and diastolic dysfunction of the LV can be understood by analysis of the relationships between LV-developed pressure and volume [<a href="#rid19">19-21</a>].</p><p>LV systolic dysfunction refers to decreases in the length-tension relationship and in myocardial contractility. Systolic dysfunction causes a shift in the Frank-Starling curve downward and to the right  (<a class="graphic graphic_figure graphicRef58693" href="/z/d/graphic/58693.html" rel="external">figure 3</a>), a downward shift in the end-systolic pressure-volume relationship (ESPVR), and a decrease in the slope of the ESPVR relationship over a range of pressures [<a href="#rid22">22</a>]. These changes are associated with a reduction in the stroke volume for a given amount of preload.</p><p>Drug therapy can alter the developed force-length relationship. For example, the administration of <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stimulates cardiac beta-adrenergic receptors, which increase myocardial cell cyclic adenosine monophosphate levels, thereby raising the intracellular calcium concentration and contractility. As a result, the ventricle is able to develop a greater force from any given fiber length. Administration of a beta blocker, on the other hand, attenuates the slope of the force-length relationship.</p><p>Hemodynamic changes associated with systolic dysfunction trigger neurohumoral activation as well as cardiac remodeling. The fall in cardiac output leads to increased sympathetic activity, which helps to restore cardiac output by increasing both contractility and heart rate. The fall in cardiac output also promotes renal salt and water retention, leading to expansion of the blood volume, thereby raising end-diastolic pressure and volume, which, via the Frank-Starling relationship, enhance ventricular performance and tend to restore the stroke volume  (<a class="graphic graphic_figure graphicRef58693" href="/z/d/graphic/58693.html" rel="external">figure 3</a>). LV hypertrophy is also part of the adaptive response to systolic dysfunction, since it unloads individual muscle fibers and thereby decreases wall stress and afterload. (See <a class="local">'Remodeling'</a> below and  <a class="medical medical_review" href="/z/d/html/3481.html" rel="external">"Pathophysiology of heart failure: Neurohumoral adaptations"</a>.)</p><p>As systolic HF progresses, the progressive decline in the maximal cardiac output generated for any given cardiac filling pressure can be represented as a series of Frank-Starling curves  (<a class="graphic graphic_figure graphicRef58693" href="/z/d/graphic/58693.html" rel="external">figure 3</a>). Flattening of the Frank-Starling curve in advanced disease means that augmentation in venous return and LV end-diastolic pressure (LVEDP) now fails to increase stroke volume. The plateau in the Frank-Starling curve represents a reduction in the heart's systolic reserve. As a result, the ability of positive inotropic agents to shift this relationship to the left and permit greater shortening becomes impaired. In terms of the pressure-volume plot, the systolic pressure-volume point is "right-shifted" in systolic HF. In addition, the ESPVR slope is decreased, which represents decreased contractility. The diastolic pressure-volume curve is initially normal in systolic HF but shifts to the right as the heart dilates. This rightward shift is due to an increase in LV volume caused by cardiac dilation  (<a class="graphic graphic_figure graphicRef79423" href="/z/d/graphic/79423.html" rel="external">figure 4</a>).</p><p>Two factors may contribute to a plateau in the pressure-volume curve:</p><p class="bulletIndent1"><span class="glyph">●</span>The heart may simply have reached its maximum capacity to increase contractility in response to increasing stretch. In vitro studies suggest that this abnormality may result from decreased calcium affinity for troponin C, and from decreased calcium availability within the myocardial cells [<a href="#rid23">23</a>]. These abnormalities may result in part from lengthening of the sarcomeres to a point that exceeds the optimal degree of overlap of thick and thin myofilaments, thereby preventing developed force from increasing in response to increasing load.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Frank-Starling relationship actually applies to LV end-diastolic volume, since it is the stretching of cardiac muscle that is responsible for the enhanced contractility. The more easily measured LVEDP is used clinically, since in relatively normal hearts, pressure and volume vary in parallel. However, cardiac compliance may be reduced with heart disease. As a result, a small increase in volume may produce a large elevation in LVEDP, but no substantial stretching of the cardiac muscle and therefore little change in cardiac output [<a href="#rid24">24</a>].</p><p></p><p>Decreased compliance due to hypertrophy and fibrosis may eventually produce disturbed diastolic function in many patients with advanced HF [<a href="#rid21">21</a>]. In this setting, there is also an upward shift in the end-diastolic pressure-volume relationship, as a higher pressure is required to achieve the same volume. In addition, disturbances in calcium handling by the sarcoplasmic reticulum leading to impaired reuptake of calcium during diastole may contribute to both systolic dysfunction due to diminished calcium stores available for release with depolarization and diastolic dysfunction (slowed relaxation) due to impaired calcium reuptake during diastole.</p><p>The failing heart is progressively more afterload-dependent, and small changes in afterload can produce large changes in stroke volume  (<a class="graphic graphic_figure graphicRef55742" href="/z/d/graphic/55742.html" rel="external">figure 5</a>). Reducing afterload in patients with HF via the administration of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or direct vasodilators (eg, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>) has the dual advantage of increasing cardiac output and, over the long term, slowing the rate of pathological remodeling. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p class="headingAnchor" id="H1127657492"><span class="h1">REMODELING</span><span class="headingEndMark"> — </span>Remodeling is defined as alteration in the structure (ie, dimensions, mass, and shape) of the heart (also called cardiac or ventricular remodeling) in response to hemodynamic load and/or cardiac injury, in association with neurohormonal activation and other factors. The process of cardiac remodeling includes structural, functional, cellular, and molecular changes involving cardiac myocytes and the interstitial collagen matrix.</p><p>Remodeling may be categorized as physiologic (adaptive) or pathologic (maladaptive) [<a href="#rid25">25,26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Physiologic remodeling is a compensatory change in the dimensions and function of the heart in response to physiologic stimuli, such as exercise and pregnancy. This type of remodeling is seen in athletes and has been called "athlete's heart." (See  <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies", section on 'Athlete's heart'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pathologic remodeling may occur with pressure overload (eg, aortic stenosis, hypertension), volume overload (eg, valvular regurgitation), or following cardiac injury and may be localized (eg, myocardial infarction [MI]) or diffuse (eg, myocarditis or idiopathic dilated cardiomyopathy). In each of these settings, remodeling may transition from an apparently compensatory process to a maladaptive one [<a href="#rid27">27</a>]. (See <a class="local">'Adaptive versus maladaptive processes'</a> below.)</p><p></p><p class="headingAnchor" id="H3343565226"><span class="h2">Structural and functional changes</span><span class="headingEndMark"> — </span>The remodeling process generally includes increases in myocardial mass, and the myocyte is the major cell involved in the remodeling process. Other components include the interstitium, fibroblasts, collagen, and coronary vasculature. Myocardial hypertrophy is most properly defined as increased cardiomyocyte size with or without an increase in overall myocardial mass; however, the term "hypertrophy" is used clinically to denote increased myocardial mass and/or wall thickness.</p><p>Three general morphologic patterns of remodeling have been described  (<a class="graphic graphic_figure graphicRef87847" href="/z/d/graphic/87847.html" rel="external">figure 6</a>) [<a href="#rid27">27,28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pressure overload leads to concentric LV remodeling with or without an overall increase in myocardial mass [<a href="#rid29">29</a>]. Concentric remodeling is characterized by increased relative wall thickness (ventricular wall thickness as compared with cavity size). With concentric hypertrophy, sarcomeres are added in parallel, and individual cardiomyocytes grow thicker.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Volume overload or isotonic exercise leads to eccentric LV hypertrophy [<a href="#rid29">29</a>]. Eccentric LV hypertrophy is characterized by increased cardiac mass and chamber volume. Relative wall thickness may be normal, increased, or decreased. With eccentric hypertrophy, sarcomeres are added in series, and individual cardiomyocytes grow longer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Following an MI, stretched, infarcted tissue increases LV volume, leading to combined volume and pressure load on noninfarcted zones and mixed concentric/eccentric hypertrophy. LV remodeling typically begins within the first few hours after the infarct, and progresses over time [<a href="#rid30">30-33</a>]. The initial remodeling phase after an MI results in repair of the necrotic area and scar formation that may, to some extent, be considered beneficial, since there is an improvement in or maintenance of LV function and cardiac output [<a href="#rid34">34,35</a>]. The entire heart may be involved, as disproportionate thinning and dilation in the infarct region (ie, infarct expansion) are accompanied by a distortion in shape of the entire heart with volume-overload hypertrophy of noninfarcted myocardium [<a href="#rid31">31,36</a>]. As the heart undergoes remodeling, it becomes less elliptical and more spherical  (<a class="graphic graphic_figure graphicRef69944" href="/z/d/graphic/69944.html" rel="external">figure 7</a>) [<a href="#rid37">37,38</a>]. There are also changes in ventricular mass, composition, and volume, all of which may adversely affect cardiac function [<a href="#rid36">36,39-42</a>]. This cellular rearrangement of the ventricular wall is associated with a significant increase in LV volume. Some studies have shown that this volume increase is not a prerequisite to maintaining LV function.</p><p></p><p class="bulletIndent1">Progressive remodeling is common after an initial, moderately large anterior wall Q-wave infarction, but is unusual after an initial small inferior wall infarction [<a href="#rid40">40</a>]. Patients with no or limited dilation at four weeks tend to remain stable, while those with progressive dilation over this period tend to deteriorate over time with loss of function in initially normally contracting myocardium (ie, pathologic remodeling) [<a href="#rid36">36,39,40</a>]. These changes are important predictors of mortality [<a href="#rid43">43</a>]. However, mechanisms other than remodeling can influence the course of heart disease, and disease progression can occur in the absence of remodeling.</p><p></p><p>The importance of remodeling as an independent risk factor has been difficult to ascertain, since factors leading to remodeling as well as the remodeling itself may be major determinants of HF prognosis. Consistent with the hypothesis that remodeling is pathogenically important in HF is the observation that angiotensin converting enzyme (ACE) inhibitors and some beta blockers, which improve survival in patients with HF, can slow and in some cases even reverse certain parameters of cardiac remodeling [<a href="#rid44">44-48</a>]. In addition, reversal of remodeling with mechanical circulatory support in combination with medical therapy is associated with improvement in LV systolic function in patients with advanced HF [<a href="#rid49">49-52</a>]. (See  <a class="medical medical_review" href="/z/d/html/3459.html" rel="external">"Treatment of advanced heart failure with a durable mechanical circulatory support device"</a> and  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p class="headingAnchor" id="H2777048163"><span class="h2">Adaptive versus maladaptive processes</span><span class="headingEndMark"> — </span>As noted above, cardiac remodeling is both an adaptive and a maladaptive process. The adaptive component enables the heart to maintain function in response to pressure or volume overload in the acute phase of cardiac injury [<a href="#rid53">53</a>].</p><p>By comparison, progressive remodeling is deleterious and associated with a poor prognosis [<a href="#rid39">39,43</a>]. There are no data to indicate when the transition from possibly adaptive to maladaptive remodeling occurs, or how this might be identified in patients. The occurrence of such a transition and its time course may be expected to vary greatly. However, once established beyond a certain phase, it is likely that remodeling actually contributes to HF progression. In addition, it has been suggested that remodeling and the myocardial changes that accompany it contribute to the pathogenesis of ventricular arrhythmias. (See  <a class="medical medical_review" href="/z/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features"</a>.)</p><p class="headingAnchor" id="H244377280"><span class="h2">Cellular and molecular changes</span><span class="headingEndMark"> — </span>Remodeling is associated with a number of cellular changes that underlie structural remodeling, including myocyte hypertrophy, loss of myocytes due to apoptosis [<a href="#rid54">54-56</a>] or necrosis [<a href="#rid57">57</a>], and fibroblast proliferation [<a href="#rid58">58</a>] and fibrosis [<a href="#rid59">59,60</a>]. These structural changes are a reflection of molecular events, which include alterations in the abundance, function, and isoforms of proteins involved in the regulation of cellular growth, survival, excitation-contraction coupling, and energetics. Many forms of myocardial remodeling are associated with increased expression of genes that are typical of the fetal heart (eg, B-type natriuretic peptide, myosin heavy chain). In addition, posttranslational changes may affect protein function and abundance that alter many aspects of cellular homeostasis.</p><p>Mechanical strain on the myocyte and circulating neurohormones plays an important role in triggering the signaling pathways that mediate hypertrophy, apoptosis, excitation-contraction coupling, and energetics [<a href="#rid34">34,61-63</a>]. (See <a class="local">'Neurohormonal activation'</a> below.)</p><p class="headingAnchor" id="H2753849840"><span class="h3">Cardiac myocytes</span><span class="headingEndMark"> — </span>Myocytes and other cardiac cell types are thought to be fundamentally involved in the remodeling process. After an insult of sufficient magnitude, myocyte numbers decrease and surviving myocytes become elongated or hypertrophied as part of a compensatory process to maintain stroke volume [<a href="#rid41">41,42</a>]; the thickness of the ventricular wall also may increase due to myocyte hypertrophy [<a href="#rid36">36,41,42</a>].</p><p>Altered loading conditions (eg, increased preload) stretch cell membranes and increase wall stress, which may play a role in inducing the expression of hypertrophy-associated genes. In cardiac myocytes, this may lead to the synthesis of new contractile proteins and the assembly of new sarcomeres. It is thought that the pattern in which these proteins are laid down determines whether the cardiac myocytes elongate or increase their diameter [<a href="#rid64">64</a>]. The increase in wall stress [<a href="#rid41">41,62</a>] may precipitate energy imbalance and ischemia, leading to a vicious cycle of increased wall stress and wall thickness, with further energy imbalance and ischemia.</p><p class="headingAnchor" id="H3185615919"><span class="h3">Collagen synthesis and degradation</span><span class="headingEndMark"> — </span>The myocardium consists of myocytes tethered and supported by a connective tissue network composed largely of fibrillar collagen. Collagen is synthesized by interstitial fibroblasts and degraded by locally produced enzymes called collagenases, such as matrix metalloproteinases (MMPs). The significance of collagen synthesis and degradation in cardiac remodeling and HF is supported by a variety of observations in humans and in animal models [<a href="#rid59">59,60,65-73</a>]. As in the cardiac myocyte, hemodynamic and neurohormonal factors act on the cardiac fibroblast and cause changes in collagen homeostasis, which contribute to abnormalities of the interstitium that affect the physical properties of the myocardium (eg, distensibility) and nutrient delivery to myocytes.</p><p class="headingAnchor" id="H667522468"><span class="h3">Apoptosis</span><span class="headingEndMark"> — </span>It has been proposed that increased apoptosis with loss of myocytes contributes to progressive LV dysfunction in chronic HF [<a href="#rid54">54</a>]. The importance of this type of cell death in human cardiac remodeling is not firmly established. However, in myocardial samples from patients who underwent heart transplantation, apoptosis was increased more than 200-fold in the failing heart [<a href="#rid56">56</a>].</p><p>Likewise, increased apoptosis is associated with the maladaptive response to sustained pressure overload (increased afterload) in the rat [<a href="#rid55">55</a>]. Furthermore, in a mouse model of HF, specific inhibition of apoptosis was beneficial [<a href="#rid74">74</a>]. Additional evidence that apoptosis is involved in adverse remodeling and HF post-MI comes from mice in which the proapoptotic protein Bnip3 was ablated [<a href="#rid75">75,76</a>].</p><p class="headingAnchor" id="H549811491"><span class="h2">Functional remodeling</span><span class="headingEndMark"> — </span>While cardiac remodeling is primarily described on a structural basis, "remodeling" also occurs at the molecular level, leading to alterations in the expression and function of proteins that have important nonstructural effects on properties such as contraction/relaxation, electrical activation, and metabolism. These molecular changes are commonly associated with structural remodeling but, not infrequently, occur in the absence of structural changes and, in either case, may have important consequences leading to alterations in substrate utilization, the genesis of arrhythmias, and abnormalities in contraction and relaxation.</p><p class="headingAnchor" id="H991292313"><span class="h2">Factors influencing cardiac remodeling</span><span class="headingEndMark"> — </span>There are a number of factors that can influence remodeling, including LV hemodynamics, blood pressure, and neurohormonal activation. The time course and extent of remodeling are influenced by a variety of factors, including the severity of the underlying disease, secondary events (such as recurrent ischemia), and treatment [<a href="#rid31">31,40,77</a>]. Following an MI, the magnitude of remodeling changes is roughly related to infarct size [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H3088023399"><span class="h3">Alterations in hemodynamic load</span><span class="headingEndMark"> — </span>Alterations in hemodynamic load caused by myocardial injury influence the remodeling process. Early LV dilation in patients with anterior wall infarction may be progressive. On the other hand, compensatory ventricular hypertrophy appears to be a delayed and limited adaptation during the first year [<a href="#rid40">40</a>]. The net effect of progressive ventricular dilation with insufficient reactive ventricular hypertrophy is a considerable increase in global LV wall tension [<a href="#rid40">40,78</a>]. A number of mechanisms may be stimulated by increased wall stress which, in the absence of effective therapy, may lead to further dilation of the heart and progressive HF [<a href="#rid42">42,79</a>].</p><p class="headingAnchor" id="H2171125159"><span class="h3">Blood pressure</span><span class="headingEndMark"> — </span>Elevated blood pressure induces structural changes in the LV (eg, hypertrophy, interstitial changes), which may result in diastolic dysfunction that may progress to HF. The functional impact of pressure overload hypertrophy may be dependent on the nature of the remodeling process. When remodeling is eccentric (LV enlargement with normal relative wall thickness, but increased wall stress), a functional impairment leading to HF was observed [<a href="#rid80">80</a>]. In contrast, HF did not occur in animals with concentric remodeling (normal chamber size, increased relative wall thickness, and normal wall stress). There was no difference between the two groups in myocardial mass or contractile function.</p><p class="headingAnchor" id="H453920579"><span class="h3">Neurohormonal activation</span><span class="headingEndMark"> — </span>Progressive HF is associated with neurohumoral activation that may be viewed initially as compensatory, but may be deleterious over the long term, in part by contributing to pathologic remodeling [<a href="#rid81">81</a>]. Types and effects of neurohormonal activation are discussed below. (See  <a class="medical medical_review" href="/z/d/html/3481.html" rel="external">"Pathophysiology of heart failure: Neurohumoral adaptations", section on 'Neurohumoral adaptations'</a>.)</p><p>The data are most compelling for activation of the renin-angiotensin-aldosterone system. Randomized trials have demonstrated that ACE inhibitors improve survival in HFrEF and can slow (and in some cases even reverse) certain parameters of cardiac remodeling. These findings indicate the importance of angiotensin II in pathologic remodeling [<a href="#rid44">44-46</a>]. Both systemic and locally generated angiotensin II may participate in this process.</p><p>Aldosterone, the secretion of which is enhanced by angiotensin II, also may participate in remodeling. The heart contains mineralocorticoid receptors and extracts aldosterone after an MI, contributing to post-infarction remodeling [<a href="#rid82">82</a>]. In addition, the secondary hyperaldosteronism commonly seen in HF may contribute to cardiac hypertrophy and fibrosis [<a href="#rid83">83,84</a>]. Part of the survival benefit associated with <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> or <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a>, which compete for the mineralocorticoid receptor, may come from reduced fibrosis [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/z/d/html/122165.html" rel="external">"Pharmacologic therapy of heart failure with reduced ejection fraction: Mechanisms of action", section on 'Mineralocorticoid receptor antagonists'</a>.)</p><p class="headingAnchor" id="H518132574"><span class="h2">Other factors</span><span class="headingEndMark"> — </span>Other factors can also contribute to remodeling, including cytokines (tumor necrosis factor-alpha [TNFa] and interleukins [IL]) [<a href="#rid86">86</a>], oxidative stress, MMPs, peripheral monocytosis [<a href="#rid87">87</a>], and endothelin. (See  <a class="medical medical_review" href="/z/d/html/3481.html" rel="external">"Pathophysiology of heart failure: Neurohumoral adaptations", section on 'Endothelin'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>HF is often associated with increases in circulating proinflammatory cytokines (eg, TNFa, IL-6, IL-1-beta and IL-2, and their soluble receptor or receptor antagonists) that become more pronounced as myocardial function deteriorates [<a href="#rid88">88-93</a>]. Since inflammatory cytokines can exert deleterious effects on the heart, it is possible that they play a role in the pathophysiology of HF. Increased levels of proinflammatory cytokines and other inflammatory markers may identify patients at increased risk of developing HF in the future [<a href="#rid94">94,95</a>], and circulating concentrations of TNFa are increased in patients with HF in proportion to the severity of the disease [<a href="#rid88">88,96</a>]. Conversely, infusion of pathophysiologic concentrations of TNFa can produce changes similar to those seen in remodeling [<a href="#rid97">97</a>]. However, the clinical significance remains uncertain, as the use of inflammatory cytokine antagonists has not been beneficial in patients with HFrEF [<a href="#rid95">95,98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oxidative stress refers to an imbalance between production of oxygen free radicals and antioxidant defenses. There is increasing literature on its potential importance in progressive HF. Although antioxidant therapies have not been shown to be of value in patients with HF, markers of oxidative stress may be elevated in patients with HF. For example, myeloperoxidase (MPO) is a leukocyte-derived enzyme that can produce a cascade of reactive oxidative species, which may lead to lipid peroxidation, scavenging of nitric oxide, and nitric oxide synthase inhibition [<a href="#rid99">99,100</a>]. Plasma MPO levels are elevated in patients with chronic HFrEF [<a href="#rid101">101</a>], and elevated plasma MPO has been associated with an increased likelihood of more advanced HF, and may be predictive of a higher rate of adverse clinical outcomes [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MMPs contribute to tissue remodeling in a number of disease states, such as an abdominal aortic aneurysm (see  <a class="medical medical_review" href="/z/d/html/15229.html" rel="external">"Clinical features and diagnosis of abdominal aortic aneurysm"</a>). MMPs have also been implicated in cardiac remodeling [<a href="#rid103">103,104</a>], and in animal models, remodeling can be attenuated by MMP inhibition [<a href="#rid72">72,73,105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral monocytosis, which occurs two to three days after an acute MI, reflects monocyte and macrophage infiltration of the necrotic myocardium. A higher peak monocyte level is associated with a larger LV end-diastolic volume and lower LVEF. A peak monocyte count ≥900/microL independently predicts HF, LV aneurysm formation, and cardiac events [<a href="#rid87">87</a>].</p><p></p><p class="headingAnchor" id="H1683611"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure (HF) is associated with a variety of interrelated structural, functional, and neurohumoral alterations with beneficial as well as maladaptive effects. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The three major determinants of the left ventricular (LV) performance (reflected as stroke volume) are the preload (venous return and end-diastolic volume), myocardial contractility (the force generated at any given end-diastolic volume), and the afterload (aortic impedance and wall stress). (See <a class="local">'Normal LV pressure-volume relationship'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The relationship between LV pressure generation and ejection can be expressed as a plot of LV pressure versus LV volume (Frank-Starling curve)  (<a class="graphic graphic_figure graphicRef73169" href="/z/d/graphic/73169.html" rel="external">figure 1</a>). (See <a class="local">'Normal LV pressure-volume relationship'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systolic dysfunction causes a shift in the Frank-Starling curve downward and to the right  (<a class="graphic graphic_figure graphicRef58693" href="/z/d/graphic/58693.html" rel="external">figure 3</a>), a downward shift in the end-systolic pressure-volume relationship (ESPVR), and a decrease in the slope of the ESPVR relationship over a range of pressures. (See <a class="local">'Pressure-volume relationships in HF'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diastolic dysfunction causes an upward–shift in the end-diastolic pressure-volume relationship. (See <a class="local">'Pressure-volume relationships in HF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Remodeling is defined as an alteration in the structure of the heart in response to hemodynamic load and/or neurohormonal activation. Pathologic remodeling may occur with pressure overload (eg, aortic stenosis, hypertension), volume overload (eg, valvular regurgitation), or following cardiac injury (eg, myocardial infarction [MI]). In each of these settings, remodeling may transition from an apparently compensatory process to a maladaptive one. (See <a class="local">'Remodeling'</a> above and <a class="local">'Adaptive versus maladaptive processes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The three general patterns of remodeling are concentric LV remodeling (in response to pressure overload), eccentric LV hypertrophy (in response to volume overload), or mixed concentric/eccentric hypertrophy as may occur following MI  (<a class="graphic graphic_figure graphicRef87847" href="/z/d/graphic/87847.html" rel="external">figure 6</a>). (See <a class="local">'Structural and functional changes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Structural remodeling is often associated with molecular events leading to changes in the expression and/or activity of proteins involved in virtually every aspect of myocardial function, including the hemodynamic, energetic, and electrical properties of the heart. (See <a class="local">'Cellular and molecular changes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Factors influencing remodeling include alterations in hemodynamic load in response to myocardial injury, blood pressure, and neurohormonal activation. (See <a class="local">'Factors influencing cardiac remodeling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The hypothesis that remodeling is pathogenically important in HF is supported by the observation that certain therapies (eg, angiotensin converting enzyme inhibitors) that improve survival in patients with HF can slow or reverse certain parameters of cardiac remodeling. (See <a class="local">'Structural and functional changes'</a> above.)</p><p></p><p class="headingAnchor" id="H736817832"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jay N Cohn, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 2011; 123:2006.</a></li><li><a class="nounderline abstract_t">Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014; 168:721.</a></li><li><a class="nounderline abstract_t">Coles AH, Tisminetzky M, Yarzebski J, et al. Magnitude of and Prognostic Factors Associated With 1-Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings. J Am Heart Assoc 2015; 4.</a></li><li><a class="nounderline abstract_t">Kapoor JR, Kapoor R, Ju C, et al. Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. JACC Heart Fail 2016; 4:464.</a></li><li><a class="nounderline abstract_t">Hsu JJ, Ziaeian B, Fonarow GC. Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. JACC Heart Fail 2017; 5:763.</a></li><li><a class="nounderline abstract_t">Nauta JF, Hummel YM, van Melle JP, et al. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? Eur J Heart Fail 2017; 19:1569.</a></li><li><a class="nounderline abstract_t">Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19:1574.</a></li><li><a class="nounderline abstract_t">Koh AS, Tay WT, Teng THK, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 2017; 19:1624.</a></li><li><a class="nounderline abstract_t">Tsuji K, Sakata Y, Nochioka K, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 2017; 19:1258.</a></li><li><a class="nounderline abstract_t">Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail 2017; 19:1597.</a></li><li><a class="nounderline abstract_t">Vedin O, Lam CSP, Koh AS, et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. Circ Heart Fail 2017; 10.</a></li><li><a class="nounderline abstract_t">Rickenbacher P, Kaufmann BA, Maeder MT, et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 2017; 19:1586.</a></li><li><a class="nounderline abstract_t">Bhambhani V, Kizer JR, Lima JAC, et al. Predictors and outcomes of heart failure with mid-range ejection fraction. Eur J Heart Fail 2018; 20:651.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Lam CS, Roger VL, et al. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 54:410.</a></li><li class="breakAll">Ross J Jr, Braunwald E. Control of cardiac performance. In: Handbook of Physiology, vol 1, The Heart, Williams &amp; Wilkins, Baltimore 1980. p.533.</li><li class="breakAll">Braunwald E. Pathophysiology of heart failure. In: Heart Disease, 4th ed, Braunwald E (Ed), Saunders, Philadelphia 1992. p.393.</li><li><a class="nounderline abstract_t">BADEER HS. CONTRACTILE TENSION IN THE MYOCARDIUM. Am Heart J 1963; 66:432.</a></li><li class="breakAll">Grossman W. Evaluation of systolic and diastolic function of the myocardium. In: Cardiac Catheterization and Angiography, 3d ed, Grossman W (Ed), Lea and Febiger, Philadelphia 1986. p.301.</li><li><a class="nounderline abstract_t">Litwin SE, Grossman W. Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol 1993; 22:49A.</a></li><li><a class="nounderline abstract_t">Holubarsch C, Ruf T, Goldstein DJ, et al. Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels. Circulation 1996; 94:683.</a></li><li><a class="nounderline abstract_t">Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 2005; 289:H501.</a></li><li><a class="nounderline abstract_t">Schwinger RH, Böhm M, Koch A, et al. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res 1994; 74:959.</a></li><li><a class="nounderline abstract_t">Komamura K, Shannon RP, Ihara T, et al. Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol 1993; 265:H1119.</a></li><li><a class="nounderline abstract_t">Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35:569.</a></li><li><a class="nounderline abstract_t">Dorn GW 2nd, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res 2003; 92:1171.</a></li><li><a class="nounderline abstract_t">Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006; 367:356.</a></li><li><a class="nounderline abstract_t">Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008; 358:1370.</a></li><li><a class="nounderline abstract_t">Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19:1550.</a></li><li><a class="nounderline abstract_t">Hochman JS, Bulkley BH. Expansion of acute myocardial infarction: an experimental study. Circulation 1982; 65:1446.</a></li><li><a class="nounderline abstract_t">Weisman HF, Bush DE, Mannisi JA, Bulkley BH. Global cardiac remodeling after acute myocardial infarction: a study in the rat model. J Am Coll Cardiol 1985; 5:1355.</a></li><li><a class="nounderline abstract_t">Korup E, Dalsgaard D, Nyvad O, et al. Comparison of degrees of left ventricular dilation within three hours and up to six days after onset of first acute myocardial infarction. Am J Cardiol 1997; 80:449.</a></li><li><a class="nounderline abstract_t">Giannuzzi P, Temporelli PL, Bosimini E, et al. Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy. Am Heart J 2001; 141:131.</a></li><li><a class="nounderline abstract_t">Ning XH, Zhang J, Liu J, et al. Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction. J Am Coll Cardiol 2000; 36:282.</a></li><li><a class="nounderline abstract_t">Cohen MV, Yang XM, Neumann T, et al. Favorable remodeling enhances recovery of regional myocardial function in the weeks after infarction in ischemically preconditioned hearts. Circulation 2000; 102:579.</a></li><li><a class="nounderline abstract_t">McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986; 74:693.</a></li><li><a class="nounderline abstract_t">Douglas PS, Morrow R, Ioli A, Reichek N. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1989; 13:311.</a></li><li><a class="nounderline abstract_t">Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 1992; 19:1136.</a></li><li><a class="nounderline abstract_t">Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993; 87:755.</a></li><li><a class="nounderline abstract_t">Rumberger JA, Behrenbeck T, Breen JR, et al. Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans. J Am Coll Cardiol 1993; 21:673.</a></li><li><a class="nounderline abstract_t">Anversa P, Olivetti G, Capasso JM. Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 1991; 68:7D.</a></li><li><a class="nounderline abstract_t">Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56:56.</a></li><li><a class="nounderline abstract_t">White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76:44.</a></li><li><a class="nounderline abstract_t">Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992; 86:431.</a></li><li><a class="nounderline abstract_t">Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993; 88:2277.</a></li><li><a class="nounderline abstract_t">Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995; 91:2573.</a></li><li><a class="nounderline abstract_t">Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29:1060.</a></li><li><a class="nounderline abstract_t">Groenning BA, Nilsson JC, Sondergaard L, et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36:2072.</a></li><li><a class="nounderline abstract_t">Kramer DG, Trikalinos TA, Kent DM, et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010; 56:392.</a></li><li><a class="nounderline abstract_t">Marinescu KK, Uriel N, Mann DL, Burkhoff D. Left ventricular assist device-induced reverse remodeling: it's not just about myocardial recovery. Expert Rev Med Devices 2017; 14:15.</a></li><li><a class="nounderline abstract_t">Koitabashi N, Kass DA. Reverse remodeling in heart failure--mechanisms and therapeutic opportunities. Nat Rev Cardiol 2011; 9:147.</a></li><li><a class="nounderline abstract_t">Saraon T, Katz SD. Reverse Remodeling in Systolic Heart Failure. Cardiol Rev 2015; 23:173.</a></li><li><a class="nounderline abstract_t">Sabbah HN, Goldstein S. Ventricular remodelling: consequences and therapy. Eur Heart J 1993; 14 Suppl C:24.</a></li><li><a class="nounderline abstract_t">Sharov VG, Sabbah HN, Shimoyama H, et al. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996; 148:141.</a></li><li><a class="nounderline abstract_t">Teiger E, Than VD, Richard L, et al. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996; 97:2891.</a></li><li><a class="nounderline abstract_t">Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336:1131.</a></li><li><a class="nounderline abstract_t">Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69:1185.</a></li><li><a class="nounderline abstract_t">Villarreal FJ, Kim NN, Ungab GD, et al. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993; 88:2849.</a></li><li><a class="nounderline abstract_t">Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979; 128:79.</a></li><li><a class="nounderline abstract_t">Weber KT, Pick R, Silver MA, et al. Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation 1990; 82:1387.</a></li><li><a class="nounderline abstract_t">Reiss K, Capasso JM, Huang HE, et al. ANG II receptors, c-myc, and c-jun in myocytes after myocardial infarction and ventricular failure. Am J Physiol 1993; 264:H760.</a></li><li><a class="nounderline abstract_t">Sadoshima J, Izumo S. Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73:413.</a></li><li><a class="nounderline abstract_t">Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension 1994; 23:587.</a></li><li><a class="nounderline abstract_t">Francis GS, McDonald KM. Left ventricular hypertrophy: an initial response to myocardial injury. Am J Cardiol 1992; 69:3G.</a></li><li><a class="nounderline abstract_t">van Krimpen C, Smits JF, Cleutjens JP, et al. DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril. J Mol Cell Cardiol 1991; 23:1245.</a></li><li><a class="nounderline abstract_t">Volders PG, Willems IE, Cleutjens JP, et al. Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol 1993; 25:1317.</a></li><li><a class="nounderline abstract_t">Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27:1281.</a></li><li><a class="nounderline abstract_t">Olivetti G, Capasso JM, Sonnenblick EH, Anversa P. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res 1990; 67:23.</a></li><li><a class="nounderline abstract_t">Iwanaga Y, Aoyama T, Kihara Y, et al. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 2002; 39:1384.</a></li><li><a class="nounderline abstract_t">López B, González A, Querejeta R, et al. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48:89.</a></li><li><a class="nounderline abstract_t">Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106:55.</a></li><li><a class="nounderline abstract_t">Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99:3063.</a></li><li><a class="nounderline abstract_t">Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 2002; 105:1983.</a></li><li><a class="nounderline abstract_t">Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest 2005; 115:565.</a></li><li><a class="nounderline abstract_t">Diwan A, Krenz M, Syed FM, et al. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J Clin Invest 2007; 117:2825.</a></li><li><a class="nounderline abstract_t">Whelan RS, Mani K, Kitsis RN. Nipping at cardiac remodeling. J Clin Invest 2007; 117:2751.</a></li><li><a class="nounderline abstract_t">Jugdutt BI. Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model. J Am Coll Cardiol 1995; 25:1718.</a></li><li><a class="nounderline abstract_t">Rumberger JA. Ventricular dilatation and remodeling after myocardial infarction. Mayo Clin Proc 1994; 69:664.</a></li><li><a class="nounderline abstract_t">Aikawa Y, Rohde L, Plehn J, et al. Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis. Am Heart J 2001; 141:234.</a></li><li><a class="nounderline abstract_t">Norton GR, Woodiwiss AJ, Gaasch WH, et al. Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol 2002; 39:664.</a></li><li><a class="nounderline abstract_t">Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248.</a></li><li><a class="nounderline abstract_t">Hayashi M, Tsutamoto T, Wada A, et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001; 38:1375.</a></li><li><a class="nounderline abstract_t">Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 32:865.</a></li><li><a class="nounderline abstract_t">Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994; 28:1863.</a></li><li><a class="nounderline abstract_t">Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102:2700.</a></li><li><a class="nounderline abstract_t">Hwang MW, Matsumori A, Furukawa Y, et al. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 2001; 38:1546.</a></li><li><a class="nounderline abstract_t">Maekawa Y, Anzai T, Yoshikawa T, et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. J Am Coll Cardiol 2002; 39:241.</a></li><li><a class="nounderline abstract_t">Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201.</a></li><li><a class="nounderline abstract_t">Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28:964.</a></li><li><a class="nounderline abstract_t">Mohler ER 3rd, Sorensen LC, Ghali JK, et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol 1997; 30:35.</a></li><li><a class="nounderline abstract_t">Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103:2055.</a></li><li><a class="nounderline abstract_t">Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92:1479.</a></li><li><a class="nounderline abstract_t">Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102:3060.</a></li><li><a class="nounderline abstract_t">Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107:1486.</a></li><li><a class="nounderline abstract_t">Murray DR, Freeman GL. Proinflammatory cytokines: predictors of a failing heart? Circulation 2003; 107:1460.</a></li><li><a class="nounderline abstract_t">Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236.</a></li><li><a class="nounderline abstract_t">Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97:1382.</a></li><li><a class="nounderline abstract_t">Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation 1997; 95:778.</a></li><li><a class="nounderline abstract_t">Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25:1102.</a></li><li><a class="nounderline abstract_t">Galijasevic S, Saed GM, Diamond MP, Abu-Soud HM. Myeloperoxidase up-regulates the catalytic activity of inducible nitric oxide synthase by preventing nitric oxide feedback inhibition. Proc Natl Acad Sci U S A 2003; 100:14766.</a></li><li><a class="nounderline abstract_t">Ng LL, Pathik B, Loke IW, et al. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 2006; 152:94.</a></li><li><a class="nounderline abstract_t">Tang WH, Tong W, Troughton RW, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007; 49:2364.</a></li><li><a class="nounderline abstract_t">Miyamoto S, Nagaya N, Ikemoto M, et al. Elevation of matrix metalloproteinase-2 level in pericardial fluid is closely associated with left ventricular remodeling. Am J Cardiol 2002; 89:102.</a></li><li><a class="nounderline abstract_t">Fedak PW, Moravec CS, McCarthy PM, et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 2006; 113:238.</a></li><li><a class="nounderline abstract_t">Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001; 103:2303.</a></li></ol></div><div id="topicVersionRevision">Topic 3506 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23747642" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555723" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25440801" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26702084" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Magnitude of and Prognostic Factors Associated With 1-Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27256749" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032140" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29067761" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : What have we learned about heart failure with mid-range ejection fraction one year after its introduction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28386917" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28948683" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A comprehensive population-based characterization of heart failure with mid-range ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28370829" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29024350" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28615366" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28295985" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226491" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Predictors and outcomes of heart failure with mid-range ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628115" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628115" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628115" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14056796" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : CONTRACTILE TENSION IN THE MYOCARDIUM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14056796" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : CONTRACTILE TENSION IN THE MYOCARDIUM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8376697" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diastolic dysfunction as a cause of heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772688" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014610" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156643" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The failing human heart is unable to use the Frank-Starling mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8238398" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716457" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12805233" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Phenotyping hypertrophy: eschew obfuscation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443044" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Controversies in ventricular remodelling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18367740" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cardiac plasticity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1534335" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7074800" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Expansion of acute myocardial infarction: an experimental study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3158687" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Global cardiac remodeling after acute myocardial infarction: a study in the rat model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285656" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of degrees of left ventricular dilation within three hours and up to six days after onset of first acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136498" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898447" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10920072" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Favorable remodeling enhances recovery of regional myocardial function in the weeks after infarction in ischemically preconditioned hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3757183" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2913109" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1532970" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8443896" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8436749" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1836099" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cellular basis of ventricular remodeling after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/124746" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Wall stress and patterns of hypertrophy in the human left ventricle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3594774" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1638712" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8222122" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7743619" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9120160" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127443" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20650361" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27871197" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Left ventricular assist device-induced reverse remodeling: it's not just about myocardial recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22143079" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25839990" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reverse Remodeling in Systolic Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8365425" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ventricular remodelling: consequences and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546201" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675703" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Apoptosis in pressure overload-induced heart hypertrophy in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9099657" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Apoptosis in the failing human heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1834362" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cardiac myocyte necrosis induced by angiotensin II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8252698" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Identification of functional angiotensin II receptors on rat cardiac fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/572867" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Histopathological types of cardiac fibrosis in myocardial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2401072" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fibrillar collagen and remodeling of dilated canine left ventricle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8456979" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : ANG II receptors, c-myc, and c-jun in myocytes after myocardial infarction and ventricular failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8348686" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8175166" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1385670" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Left ventricular hypertrophy: an initial response to myocardial injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1803017" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7507999" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8531210" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Regulation of collagen degradation in the rat myocardium after infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2364493" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11955860" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16814653" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10880048" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10368126" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11997287" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15765138" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Death begets failure in the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17909626" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17909620" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Nipping at cardiac remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7759729" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8015331" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ventricular dilatation and remodeling after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174337" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849866" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1351488" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11691511" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10888242" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Induction of cardiac fibrosis by aldosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7867040" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Aldosterone and cardiac fibrosis: in vitro studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11094035" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11691538" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788214" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609343" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8837575" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207618" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11319194" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7664430" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120695" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Plasma cytokine parameters and mortality in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654604" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654598" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Proinflammatory cytokines: predictors of a failing heart?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2195340" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9577950" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9054727" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cytokines and cardiac contractile function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15790935" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Myeloperoxidase and cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657339" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Myeloperoxidase up-regulates the catalytic activity of inducible nitric oxide synthase by preventing nitric oxide feedback inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16824837" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572253" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779539" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Elevation of matrix metalloproteinase-2 level in pericardial fluid is closely associated with left ventricular remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401770" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11342481" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
